Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure

A Prospective, Multi-center, Single-arm, Open-label Phase II Clinical Study of Pirtobrutinib Combined With Sonrotoclax and Rituximab in Patients With Relapsed/Refractory High-risk Mantle Cell Lymphoma Previously Treated With a Covalent BTKi.

This single-arm, multicenter, open-label phase II study aims to evaluate the efficacy and safety of pirtobrutinib plus sonrotoclax and rituximab in adults with high-risk relapsed/refractory mantle cell lymphoma after failure of prior covalent BTK-inhibitor therapy. **Approximately 35 patients are planned to be enrolled**. Subjects will receive 28-day cycles of the triple-drug regimen. Participants achieving complete response with undetectable MRD at cycle 12 may stop treatment; others may continue up to 24 cycles. The primary endpoint is the CR-uMRD rate at cycle 12. Secondary endpoints include ORR, CRR, DOR, PFS, OS and safety. Exploratory biomarker and quality-of-life analyses will also be performed.

Panoramica dello studio

Descrizione dettagliata

This is a prospective single-arm, multicenter, open-label phase II trial. **Approximately 35 adult patients with histologically-confirmed high-risk relapsed/refractory mantle cell lymphoma who progressed after covalent BTK-inhibitor-containing therapy are planned to be enrolled**. Eligible patients will receive pirtobrutinib 200 mg once-daily, sonrotoclax ramp-up to 320 mg once-daily, and rituximab 375 mg/m² on day 1 of each 28-day cycle. Patients with CR-uMRD after 12 cycles may discontinue study treatment; remaining patients can continue therapy for a maximum of 24 cycles. Tumor response, MRD and safety (CTCAE 5.0) will be assessed regularly. All patients will receive long-term survival follow-up after treatment. Biomarker and patient-reported quality-of-life assessments will be conducted as exploratory analyses.

Tipo di studio

Interventistico

Iscrizione (Stimato)

35

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Cina, 300060
        • Tianjin Medical University Cancer Insititute & Hospital
        • Contatto:
          • Huilai Zhang, PHD
          • Numero di telefono: 086-02223340123
          • Email: zhlwgq@126.com

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • 1.Histopathologically-confirmed mantle cell lymphoma (MCL) with documented t(11;14)(q13;q32) translocation and/or cyclin-D1 over-expression, accompanied by relevant biomarkers (e.g., CD5, CD19, CD20, or PAX5). All subjects must provide sufficient archived or fresh tumor tissue samples for immunohistochemistry (IHC) testing.

  • 2.Age ≥ 18 years, male or female.

  • 3. Received at least one prior line of systemic therapy containing a covalent BTK-inhibitor.

  • 4.Histopathologically-confirmed high-risk MCL, defined as meeting at least one of the following criteria: POD24, complex karyotype, TP53 mutation, del(17p), high-risk MIPI score, blastoid / pleomorphic variant, Ki-67 ≥ 30 %, bulky disease.

  • 5.Presence of at least one measurable lesion. Measurable disease is defined as a tumor mass ≥ 1.5 cm in one or two dimensions; splenic lesions are considered measurable.

  • 6.Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.

  • 7.Adequate hematological function:

    1. Absolute neutrophil count (ANC) ≥ 1 × 10⁹/L without growth-factor support within 7 days prior to testing;
    2. Platelet count ≥ 75 × 10⁹/L, or ≥ 50 × 10⁹/L in the setting of bone-marrow involvement; no growth-factor support or transfusion within 7 days prior to testing.
  • 8.Adequate hepatic function:

    1. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × upper limit of normal (ULN);
    2. Total bilirubin ≤ 2 × ULN, except for subjects with confirmed Gilbert syndrome, in whom bilirubin up to 5 × ULN is permitted.
  • 9.Adequate renal function:

    1. Creatinine clearance ≥ 60 mL/min (estimated by the Cockcroft-Gault formula, or eGFR calculated using the Modification of Diet in Renal Disease [MDRD] formula);
    2. Serum creatinine ≤ 1.5 × ULN.
  • 10.International normalized ratio (INR) ≤ 1.5 × ULN and activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.

  • 11.For females of child-bearing potential, two negative pregnancy tests (at least one serum pregnancy test) are required prior to treatment initiation. The first test must be performed 10-14 days before the first dose of sonrotoclax; the second test must be performed within 24 hours before the first dose of sonrotoclax.

  • 12.Females of child-bearing potential must agree to use two reliable contraceptive methods (one highly-effective method plus one additional effective method), starting 4 weeks prior to initiating sonrotoclax, throughout study participation, and for at least 90 days after the last dose of pirtobrutinib or 12 months after the last dose of rituximab (whichever is longer). Highly-effective contraception includes abstinence, hysterectomy, bilateral oophorectomy with 6-month amenorrhea, intrauterine system, and hormonal contraception (e.g., injectable or oral contraceptives). Male subjects must be vasectomized or use barrier contraception while their female partners employ effective contraception as described above. Male subjects must refrain from sperm donation during the study and for at least 90 days after the last dose of pirtobrutinib and sonrotoclax, or for 12 months after the last dose of rituximab (whichever is longer).

  • 13.Estimated life expectancy > 3 months.

  • 14.Capable of providing written informed consent, and able to understand and comply with study requirements.

Exclusion Criteria:

  • 1. Current or suspected central nervous system (CNS) involvement of mantle cell lymphoma, or a prior history of CNS-involved disease.

  • 2. Prior treatment with a BCL-2 inhibitor or pirtobrutinib.

  • 3. Major surgery within 4 weeks prior to screening. Note: If a subject has undergone major surgery, they must have fully recovered from any toxicities and/or complications of the intervention before receiving the first dose of study drug.

  • 4. History of other active malignant disease within 2 years before entering the study, with the following exceptions: (1) adequately-treated carcinoma in-situ of the cervix; (2) localized basal-cell or squamous-cell skin carcinoma; (3) previously-diagnosed malignancy that has been controlled with curative-intent local treatment (surgery or other modalities).

  • 5. Active, uncontrolled systemic fungal, bacterial, or viral infection (defined as persistent signs/symptoms related to infection with no improvement despite appropriate antibiotic, antiviral, and/or other therapy).

  • 6. Known human immunodeficiency virus (HIV) infection, or serology suggestive of active hepatitis B or hepatitis C infection, as follows:

    1. Subjects who are hepatitis B core antibody (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-negative must have a negative HBV-PCR result prior to the first study-drug dose. Subjects who are HBsAg-positive or HBV-DNA-positive are excluded.
    2. Subjects with positive hepatitis C antibody must have a negative HCV-RNA result before the first dose of study drug. Subjects with positive HCV-PCR are excluded.
  • 7. Clinically significant cardiovascular disease, including:

    1. Myocardial infarction within 6 months before screening;
    2. Unstable angina within 3 months before screening;
    3. Clinically significant arrhythmias (e.g., sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes);
    4. QTcF (Fridericia correction) > 480 msec;
    5. History of second-degree type-II or third-degree atrioventricular (AV) block;
    6. New York Heart Association (NYHA) class III or IV congestive heart failure.
  • 8. History of severe bleeding disorders, such as hemophilia A, hemophilia B, von Willebrand disease, or history of spontaneous bleeding requiring transfusion or other medical intervention.

  • 9. History of deep-vein thrombosis (DVT) or pulmonary embolism (PE) within the previous 12 months.

  • 10. History of a major cerebrovascular event (including stroke or intracranial hemorrhage) within 6 months before the first dose of study drug.

  • 11. Requiring ongoing treatment with strong or moderate CYP3A inhibitors or CYP3A inducers. Subjects who have received strong/moderate CYP3A inhibitors or inducers within 7 days (or less than 5 drug half-lives) before the first study-drug dose are excluded. Subjects receiving moderate CYP3A inhibitors may be considered for enrollment after a minimum 7-day wash-out period.

  • 12. Requiring anticoagulation with warfarin or an equivalent vitamin-K antagonist (e.g., phenprocoumon) within 7 days of the first study-drug dose.

  • 13. Active bleeding gastrointestinal ulcer, except cases attributable to mantle-cell lymphoma identified on endoscopy.

  • 14. Known hypersensitivity to urate-lowering agents.

  • 15. History of toxic epidermal necrolysis or Stevens-Johnson syndrome.

  • 16. Pregnant or breastfeeding women.

  • 17. Known hypersensitivity to any of the study drugs.

  • 18. Any psychiatric or cognitive disorder that may limit the subject's ability to understand, provide informed consent, or comply with study requirements.

  • 19. Subjects with active drug or alcohol abuse. Any life-threatening disease, medical condition, or organ-system dysfunction that, in the investigator's judgment, may jeopardize subject safety or introduce additional risks to participation in the study.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Pirtobrutinib + Sonrotoclax + Rituximab Combination Therapy

Patients receive pirtobrutinib 200 mg once daily continuously, sonrotoclax dose-escalated to 320 mg once daily, plus rituximab 375 mg/m² on Day 1 of each 28-day cycle. Treatment may stop at Cycle 12 for patients achieving CR-uMRD, with a maximum treatment duration of 24 cycles.

200 mg oral once daily, continuous administration throughout the treatment cycle (28-day cycle)

Dose ramp-up within the first 4 weeks to the target dose of 320 mg oral once daily, continuous dosing.

375 mg/m² intravenous infusion administered on Day 1 of each 28-day treatment cycle.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Rate of complete response with undetectable minimal residual disease (CR-uMRD) at Cycle 12
Lasso di tempo: At the end of Cycle 12 (each cycle is 28 days)

Proportion of patients with high-risk relapsed/refractory mantle cell lymphoma who achieve complete response (CR) with undetectable minimal residual disease (uMRD) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy. uMRD is defined as peripheral blood MRD <10-⁵ as measured by the clonoSEQ assay.

At the end of Cycle 12 (each cycle is 28 days)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Overall Response Rate (ORR) at Cycle 12
Lasso di tempo: At the end of Cycle 12 (each cycle is 28 days)

Proportion of patients achieving complete response (CR) or partial response (PR) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy, assessed per standard lymphoma response criteria.

At the end of Cycle 12 (each cycle is 28 days)
Complete Response Rate (CRR) at Cycle 12
Lasso di tempo: At the end of Cycle 12 (each cycle is 28 days)

Proportion of patients achieving complete response (CR) after 12 cycles of pirtobrutinib, sonrotoclax, and rituximab combination therapy, assessed per standard lymphoma response criteria.

At the end of Cycle 12 (each cycle is 28 days)
Duration of Response(DOR)
Lasso di tempo: From initial objective response until progression, death, or the end of study follow-up, maximum 36-months after treatment initiation

The length of time between the achievement of criteria for response to treatment (first documented complete or partial response) and the first documented relapse or progression.

From initial objective response until progression, death, or the end of study follow-up, maximum 36-months after treatment initiation
Progression-free survival (PFS)
Lasso di tempo: From first drug dose until progression, death, or end of study follow-up, maximum 36-months after treatment initiation

The time from the enrollment of a subject to the occurrence of (in any way) progression of disease or Death for any reason. patients with indeterminate recurrence or Death at the last follow-up, defined as the date of the last Investigation

From first drug dose until progression, death, or end of study follow-up, maximum 36-months after treatment initiation
Overall Survival (OS)
Lasso di tempo: From first drug dose until death or end of study follow-up, maximum 36-months after treatment initiation

Time from the first dose of study treatment to death from any cause. Patients still alive will be censored at the date last known to be alive or the end-of-study follow-up.

From first drug dose until death or end of study follow-up, maximum 36-months after treatment initiation
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Lasso di tempo: From the first dose of study treatment until 30 days after the last dose of study treatment

Adverse events (AEs) and serious adverse events (SAEs) will be monitored throughout the study based on physical examination findings and laboratory test results, and graded according to NCI-CTCAE Version 5.0.

From the first dose of study treatment until 30 days after the last dose of study treatment
MRD Conversion and Subsequent MRD Relapse Rate
Lasso di tempo: At the end of Cycle 12 (each cycle is 28 days), at the end of Cycle 24 (each cycle is 28 days)

Rate of MRD negativity and subsequent MRD relapse assessed by high-sensitivity flow cytometry.Rate of conversion to MRD negativity and subsequent MRD relapse, assessed by high-sensitivity flow cytometry.

At the end of Cycle 12 (each cycle is 28 days), at the end of Cycle 24 (each cycle is 28 days)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

8 dicembre 2026

Completamento primario (Stimato)

8 dicembre 2028

Completamento dello studio (Stimato)

8 dicembre 2030

Date di iscrizione allo studio

Primo inviato

9 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

12 novembre 2026

Primo Inserito (Effettivo)

18 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

18 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

12 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi